Recombinant Factor VIIa plus Surgery for Intracerebral Hemorrhage
نویسندگان
چکیده
منابع مشابه
Recombinant Human Coagulation Factor VIIa for Intracerebral Hemorrhage.
with expanding intracranial bleeds associated with neurologic deterioration, or where urgent surgical intervention is indicated. Often, a single dose of 40 microg/Kg dramatically corrects the coagulopathy in minutes, allowing stabilization of clot expansion and safe neurosurgical intervention, while fresh frozen plasma, vitamin K and other products are administered for subacute maintenance of n...
متن کاملPotential applicability of recombinant factor VIIa for intracerebral hemorrhage.
BACKGROUND AND PURPOSE To date, there are no proven, effective treatments for intracerebral hemorrhage (ICH) beyond supportive medical care. A recent randomized, blinded, placebo-controlled trial of recombinant factor VIIa (rFVIIa) administered intravenously within 4 hours of ICH onset reported a reduction in morbidity and mortality compared with placebo. We sought to determine the potential ap...
متن کاملSafety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
BACKGROUND AND PURPOSE Hematoma growth occurs in 38% of intracerebral hemorrhage (ICH) patients scanned by computed tomography (CT) within 3 hours of onset. Activated recombinant factor VII (rFVIIa) promotes hemostasis at sites of vascular injury and may minimize hematoma growth after ICH. METHODS In this randomized, double-blind, placebo-controlled, dose-escalation trial, 48 subjects with IC...
متن کاملCost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
BACKGROUND Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage (ICH) is safe, limits ICH growth, and improves outcomes. We sought to determine the cost-effectiveness of rFVIIa for acute ICH treatment, using published Phase II data. We hypothesized that rFVIIa would have a...
متن کاملUse of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis
Symptomatic intracerebral hemorrhage (sICH) occurs in up to 7% of stroke patients treated with thrombolytic therapy. There are limited data on the effectiveness of the reversal agents used for intravenous tissue plasminogen activator related intracranial bleeds. We report a patient with sICH following intravenous thrombolysis whose intracerebral hemorrhage continued to expand despite treatment ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
سال: 2008
ISSN: 0317-1671,2057-0155
DOI: 10.1017/s0317167100009343